Sio Capital Management, LLC

13F Portfolio Filings

Latest 13F report
Q2 2024 - Aug 14, 2024
Value $
$265M
Signature - Title
Jin W. Lee - Chief Compliance Officer
Location
600 Third Avenue, 2 Nd Floor, New York, NY
Holdings Value
Quarter Holdings Value $ Bought Sold Net Top Holdings Form Type Date Filed
Q2 2024 46 $265M +$170M -$170M +$433K LH, TFX, ZBH, SNN, OGN 13F-HR 8/14/2024, 02:00 PM
Q1 2024 48 $287M +$121M -$250M -$129M LH, CI, GMED, MDGL, GSK 13F-HR 5/15/2024, 01:00 PM
Q4 2023 39 $388M +$167M -$142M +$25.3M MRTX, GRCL, LH, CI, GMED 13F-HR 2/13/2024, 02:00 PM
Q3 2023 52 $323M +$151M -$74.4M +$76.9M LH, GMED, GSK, UTHR, CI 13F-HR 11/14/2023, 02:00 PM
Q2 2023 41 $283M +$156M -$83M +$73.4M GEHC, LH, CI, BCYC, UTHR 13F-HR 8/14/2023, 03:36 PM
Q1 2023 44 $202M +$105M -$74M +$30.5M CNC, CI, BCYC, COR, UTHR 13F-HR 5/12/2023, 04:00 PM
Q4 2022 41 $187M +$55.8M -$119M -$63M MSAC, BCYC, CI, OGN, UTHR 13F-HR 2/13/2023, 04:00 PM
Q3 2022 43 $234M +$64.7M -$79.3M -$14.7M COR, GSK, MSAC, BCYC, OGN 13F-HR 11/14/2022, 12:49 PM
Q2 2022 59 $254M +$134M -$111M +$23M COR, MSAC, OGN, CI, INGN 13F-HR 8/15/2022, 01:34 PM
Q1 2022 61 $248M +$70.3M -$134M -$63.4M MSAC, CI, MRK, SNY, LH 13F-HR 5/16/2022, 02:00 PM
Q4 2021 67 $328M +$130M -$95M +$35M CI, MSAC, CRIS, MRK, CAH 13F-HR 2/14/2022, 02:03 PM
Q3 2021 59 $310M +$68.9M -$101M -$32.2M CI, CRIS, GLD, SOLY, UHS 13F-HR 11/15/2021, 03:00 PM
Q2 2021 70 $368M +$72.9M -$166M -$92.9M CRIS, CI, SOLY, GLD, AVAH 13F-HR 8/16/2021, 04:00 PM
Q1 2021 85 $478M +$144M -$157M -$13.6M CRIS, CI, CAH, GLD, SOLY 13F-HR 5/14/2021, 04:00 PM
Q4 2020 86 $457M +$134M -$217M -$83.6M CRIS, GLD, SPRB, CHRS, ALBO 13F-HR 2/16/2021, 01:03 PM
Q3 2020 85 $451M +$223M -$94.4M +$128M GLD, CHRS, MCK, JNJ, HRC 13F-HR 11/16/2020, 02:00 PM
Q2 2020 72 $323M +$143M -$158M -$15.5M CHRS, GLD, MCK, TEVA, GWPH 13F-HR 8/14/2020, 02:00 PM
Q1 2020 66 $280M +$156M -$178M -$22.2M AMGN, MCK, CHRS, GWPH, BIIB 13F-HR 5/15/2020, 03:40 PM
Q4 2019 58 $324M +$124M -$108M +$16.1M GWPH, AGN, CHRS, MDT, HCA 13F-HR 2/14/2020, 04:00 PM
Q3 2019 52 $281M +$119M -$141M -$22M GWPH, JNJ, AGN, HCA, WCG 13F-HR 11/14/2019, 04:00 PM
Q2 2019 58 $323M +$145M -$140M +$5.4M GWPH, HCA, WCG, GSKXXXX, MRTX 13F-HR 8/14/2019, 04:00 PM
Q1 2019 58 $323M +$155M -$112M +$43.4M CVS, BIIB, GILD, HCA, MDT 13F-HR 5/15/2019, 04:00 PM
Q4 2018 66 $259M +$157M -$94.5M +$62.5M MDT, SNY, ALNY, COR, CI 13F-HR 2/14/2019, 04:00 PM
Q3 2018 51 $233M +$114M -$55.3M +$58.4M GSK, CI, KURA, AET, SNY 13F-HR 11/14/2018, 04:00 PM
Q2 2018 40 $161M +$82.8M -$79.4M +$3.37M KURA, ELV, HCA, MEIP, ICLR 13F-HR 8/14/2018, 04:02 PM
Q1 2018 28 $160M +$104M -$53.1M +$50.9M CBIO, SNY, KURA, ELV, BIIB 13F-HR 5/15/2018, 04:00 PM
Q4 2017 33 $106M +$48.2M -$74M -$25.8M GSK, AET, ELV, QTNT, KURA 13F-HR 2/14/2018, 04:01 PM
Q3 2017 43 $125M +$59.4M -$67.7M -$8.27M QTNT, ADMP, AET, AXGT, GSK 13F-HR 11/14/2017, 04:00 PM
Q2 2017 40 $132M +$41.2M -$52.9M -$11.7M QTNT, SNY, AET, PHG, PBYI 13F-HR 8/14/2017, 04:00 PM
Q1 2017 36 $130M +$61.2M -$39.5M +$21.7M QTNT, SNY, GSK, PHG, BIIB 13F-HR 5/15/2017, 04:00 PM
Q4 2016 28 $95.9M +$44.7M -$42.1M +$2.62M QTNT, GSK, PHG, HRC, TRHC 13F-HR 2/14/2017, 04:00 PM
Q3 2016 26 $104M +$30.5M -$67.3M -$36.8M QTNT, PHG, CAH, SNY, TRHC 13F-HR 11/15/2016, 09:38 AM
Q2 2016 32 $132M +$45.6M -$133M -$87.3M QTNT, BIIB, CAH, PHG, SNY 13F-HR 8/15/2016, 04:31 PM
Q1 2016 38 $228M +$136M -$104M +$31.9M QTNT, NEOS, MCK, AMGN, ANTH 13F-HR 5/16/2016, 04:01 PM
Q4 2015 41 $224M +$128M -$54.7M +$73.1M QTNT, DYAX, SNY, NEOS, MCK 13F-HR 2/16/2016, 04:01 PM
Q3 2015 35 $144M +$74.5M -$35.3M +$39.2M QTNT, NEOS, JNJ, MDT, CAH 13F-HR 11/13/2015, 04:15 PM
Q2 2015 31 $124M +$73.7M -$38.9M +$34.7M QTNT, GSK, RXDX, FLML, PFNX 13F-HR 8/14/2015, 04:06 PM
Q1 2015 23 $89.3M +$37.4M -$79.2M -$41.8M QTNT, PFNX, MRK, UTHR, CAH 13F-HR 5/15/2015, 04:01 PM
Q4 2014 30 $127M $0 $0 QTNT, SNY, GSK, F113PS, ADMP 13F-HR 2/17/2015, 04:14 PM